Alkermes (NASDAQ:ALKS) Releases FY 2026 Earnings Guidance

Alkermes (NASDAQ:ALKS) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of -0.798–0.680 for the period, compared to the consensus estimate of 1.630. The company issued revenue guidance of $1.7 billion-$1.8 billion, compared to the consensus revenue estimate of $1.7 billion.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on ALKS shares. Bank of America raised their price target on Alkermes from $33.00 to $34.00 and gave the company a “neutral” rating in a research note on Friday, February 20th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Alkermes in a report on Monday, December 29th. Zacks Research lowered shares of Alkermes from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 19th. Truist Financial boosted their price objective on shares of Alkermes from $50.00 to $55.00 and gave the company a “buy” rating in a report on Monday, November 17th. Finally, Needham & Company LLC upped their price objective on Alkermes from $43.00 to $44.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, Alkermes presently has a consensus rating of “Moderate Buy” and an average price target of $44.00.

Alkermes Stock Down 5.2%

Shares of NASDAQ:ALKS traded down $1.75 on Wednesday, reaching $31.64. 1,196,835 shares of the company’s stock were exchanged, compared to its average volume of 1,963,265. Alkermes has a fifty-two week low of $25.17 and a fifty-two week high of $36.32. The business’s 50-day moving average is $31.38 and its two-hundred day moving average is $30.17. The firm has a market capitalization of $5.22 billion, a price-to-earnings ratio of 15.67 and a beta of 0.49.

Alkermes (NASDAQ:ALKS) last released its earnings results on Wednesday, February 25th. The company reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.14). The company had revenue of $384.55 million during the quarter, compared to analysts’ expectations of $380.44 million. Alkermes had a return on equity of 21.81% and a net margin of 22.27%.The firm’s quarterly revenue was down 10.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.05 EPS. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. Analysts predict that Alkermes will post 1.31 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Shane Cooke sold 61,200 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $34.57, for a total value of $2,115,684.00. Following the completion of the transaction, the director directly owned 103,744 shares in the company, valued at approximately $3,586,430.08. The trade was a 37.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Craig C. Hopkinson sold 9,000 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $33.93, for a total transaction of $305,370.00. Following the sale, the executive vice president directly owned 57,740 shares of the company’s stock, valued at $1,959,118.20. This represents a 13.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 148,148 shares of company stock worth $5,028,378. Insiders own 4.40% of the company’s stock.

Alkermes News Summary

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Wolfe Research initiated coverage with an “outperform” rating and $45 price target — provides a bullish analyst catalyst and a sizable upside to current levels. Wolfe Research initiation
• Positive Sentiment: Board announced an orderly CEO succession: Richard Pops will retire July 31, 2026, and COO Blair Jackson will become CEO Aug. 1, 2026 — reduces leadership uncertainty and signals continuity. CEO Succession Press Release
• Neutral Sentiment: Alkermes to present at the TD Cowen Health Care Conference — visibility event for investors but not an immediate earnings driver. Conference presentation
• Neutral Sentiment: Media noted the company recently closed the Avadel acquisition ahead of these results — strategic context for revenue/growth but impact depends on integration and margins. Avadel acquisition coverage
• Neutral Sentiment: Reported short-interest data in the feed is noisy/zeroed out and not informative for near‑term squeezes (no clear signal).
• Negative Sentiment: Q4 EPS missed: Alkermes reported $0.29 EPS vs. consensus $0.43, and revenue $384.6M (slightly above estimates) with revenue down ~10.6% y/y — suggests margin pressure and weaker profitability versus expectations. Earnings press release / slides Conference call
• Negative Sentiment: Crucial FY‑2026 guidance missed expectations: Alkermes updated EPS guidance to -0.798 to -0.680 vs. consensus ~1.63 — a materially weaker profitability outlook that explains the negative market reaction despite revenue guidance near street. FY2026 guidance press release

Institutional Investors Weigh In On Alkermes

Several large investors have recently made changes to their positions in the stock. Johnson Financial Group Inc. bought a new stake in shares of Alkermes during the third quarter worth approximately $31,000. UMB Bank n.a. grew its stake in shares of Alkermes by 57.6% in the fourth quarter. UMB Bank n.a. now owns 1,220 shares of the company’s stock valued at $34,000 after acquiring an additional 446 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its position in Alkermes by 1,041.4% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,324 shares of the company’s stock worth $37,000 after acquiring an additional 1,208 shares during the period. Osaic Holdings Inc. boosted its holdings in Alkermes by 56.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,945 shares of the company’s stock valued at $56,000 after purchasing an additional 701 shares during the period. Finally, T. Rowe Price Investment Management Inc. acquired a new position in shares of Alkermes during the 4th quarter worth approximately $59,000. Institutional investors and hedge funds own 95.21% of the company’s stock.

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.